CSI Market
Sign In | Register

Karyopharm Therapeutics Inc (KPTI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KPTI quarterly Cash Flow →
This page allows investors to follow Karyopharm Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-196.04
Depreciation & amortization0.30
Amortization of Other Assets10.55
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.70
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation14.05
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt62.37
Noncash Consulting Expense-
Increase Decrease In Operating Lease Right Of Use Asset1.34
Marketable Securities Gain Loss-
Embedded Derivative Gain Loss On Embedded Derivative Net-0.71
Increase Decrease In Contract With Customer Liability-
Research And Development In Process-
Interest Expense Long Term Debt6.26
Covertible Senior Notes Issued With Warrant In Exchange Of Deferred Royalty Obligation-
Notes Issued-
Stock Issued-
Increase Decrease In Operating Lease Liabilities-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable4.59
Increase (Decrease) in Accounts Payable-1.10
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities19.06
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets4.13
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.85
Discontinued operations0.00
Net Cash flow from Operating Activities-75.37
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities43.38
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities43.38
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-6.46
Long-term debt - borrowings27.25
Long-term debt - repayments-0.25
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.76
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-62.81
Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs-
Proceeds From Payments For Common Stock Issuance Net-
Proceeds From Deferred Royalty Obligation-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents62.81
Proceeds From Deferred Royalty Obligation Net-
Proceeds From Amended Revenue Interest Agreement-
Payment Of Deferred Royalty Obligation-
Proceeds From Issuance Of Common Stock And Warrants In Private Placement Offering8.75
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities30.05
Effect of exchange rate on cash flow0.02
Discontinued operations0.00
Free Cash Flow-75.37
Total Cash Flow-1.92
4 historic quarters locked

Sign in to unlock the full Karyopharm Therapeutics Inc cash flow history.

Sign In Create Free Account

About Karyopharm Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 12, 2026
  • Source: kpti-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-049397

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License